Correlation of HER-2/neu overexpression with mammography and age distribution in primary breast carcinomas

Acad Radiol. 2006 Oct;13(10):1211-8. doi: 10.1016/j.acra.2006.06.015.

Abstract

Rationale and objectives: HER-2/neu is a valuable prognostic and therapeutic marker in primary breast carcinoma. The objective of this study was to determine the mammographic and patient characteristics (age) that correlate with HER-2/neu overexpression in primary breast carcinoma.

Materials and methods: HER-2/neu characteristics and preoperative mammograms were available in 498 patients with 543 primary breast carcinomas (526 invasive carcinomas and 17 ductal carcinoma in situ). HER-2/neu status was determined by immunohistochemistry and fluorescence in situ hybridization. For evaluation of patient age distribution, age was divided into 5 groups. For mammography, breast composition and abnormal findings were categorized. Abnormal findings were divided into mass, calcification, architectural distortion, asymmetric density, or none.

Results: For age distribution, women under than 50 years had more frequent HER-2/neu overexpression than women aged 60-69 years (P < .05). On mammography, there was no significant correlation between breast composition and HER-2/neu status (P > .05). Calcifications were more significantly frequent in carcinomas with HER-2/neu overexpression (56%) than in those without HER-2/neu overexpression (40%) (P = .001). Of the 242 carcinomas with calcifications on mammography, fine linear morphology was more significantly frequent in carcinomas with HER-2/neu overexpression (20%) when compared with those without HER-2/neu overexpression (10%) (P = .023). Diffuse distribution of calcifications was more common in carcinomas with HER-2/neu overexpression (11%) compared with carcinomas without HER-2/neu overexpression (5%) (P = .051).

Conclusion: HER-2/neu overexpression in primary breast carcinoma is correlated with patients' age (under age 50) and calcifications at mammography.

MeSH terms

  • Adult
  • Age Distribution
  • Aged
  • Aged, 80 and over
  • Biomarkers, Tumor / analysis*
  • Breast Neoplasms / diagnostic imaging*
  • Breast Neoplasms / epidemiology
  • Breast Neoplasms / metabolism*
  • Carcinoma / diagnostic imaging*
  • Carcinoma / epidemiology
  • Carcinoma / metabolism*
  • Female
  • Humans
  • Incidence
  • Mammography / statistics & numerical data*
  • Middle Aged
  • Neoplasm Proteins / analysis
  • North Carolina / epidemiology
  • Prognosis
  • Receptor, ErbB-2 / analysis*
  • Reproducibility of Results
  • Risk Assessment / methods
  • Risk Factors
  • Sensitivity and Specificity
  • Statistics as Topic

Substances

  • Biomarkers, Tumor
  • Neoplasm Proteins
  • Receptor, ErbB-2